Skip to main content
SpringerLink
Log in

HPV-vaccinatie

  • Published:
Bijblijven

Samenvatting

In 2009 is vaccinatie tegen humaan papillomavirus (HPV) opgenomen in het Nederlandse Rijksvaccinatieprogramma voor 13-jarige meisjes. HPV is een seksueel overdraagbaar virus dat veel voorkomt. De meeste infecties met HPV gaan vanzelf weer over en brengen geen klachten met zich mee. Wanneer het lichaam het virus niet opruimt, kan HPV genitale wratten en kanker veroorzaken. De meest voorkomende vorm van kanker die door HPV wordt veroorzaakt is baarmoederhalskanker. Er zijn momenteel drie verschillende vaccins goedgekeurd voor gebruik in Europa: het bivalente (HPV16/18), het quadrivalente (HPV16/18/6/11) en het nonavalente (HPV16/18/6/11/31/33/45/52/58) vaccin. Alle vaccins laten een goede protectie zien tegen het krijgen van een HPV-infectie, en tegen voorstadia van baarmoederhalskanker. Op grond daarvan verwacht men dat het vaccin op langere termijn ook bescherming biedt tegen het krijgen van baarmoederhalskanker. Het risico op serieuze bijwerkingen is nihil. Het effect van de HPV-vaccinatie op het bevolkingsonderzoek naar baarmoederhalskanker is nog niet bekend. In 2023 zullen de eerste cohorten die gevaccineerd zijn tegen HPV uitgenodigd worden voor deelname aan het bevolkingsonderzoek.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatuur

  1. Coupe VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer. 2008;98(3):646–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Huijsmans CJ, Geurts-Giele WR, Leeijen C. et al. Cervical cancer screening in the Netherlands: determination of HPV prevalence using three different systems. Eurogin conference, Salzburg. 2016.

    Google Scholar 

  3. Garland SM, Kjaer SK, Munoz N, et al. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience. Clin Infect Dis. 2016;63(4):519–27.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Centers for Disease Control and Prevention, Department of Health and Human Services, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. Human papillomavirus (HPV) infection. MMWR Morb Mortal Wkly Rep. 2010;59(12):69–67.

    Google Scholar 

  5. Egelkrout EM, Galloway DA. The biology of genital human papillomaviruses. In: Holmes KK et al (redactie). Sexually transmitted diseases, 4e druk. New York: McGraw-Hill; 2008. pp. 463–87.

    Google Scholar 

  6. Lacey CJN, Woodhall SC, Wikstrom A, Ross J. IUSTI: 2010 European guideline for the management of anogenital warts in adults, V5 CL 231010. 2010.

    Google Scholar 

  7. Broek IV van den, Verheij RA, Dijk CE van, Koedijk FD, Sande MA van der, Bergen JE van. Trends in sexually transmitted infections in the Netherlands, combining surveillance data from general practices and sexually transmitted infection centers. BMC Fam Pract. 2010;11:39.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Aar F van, Koedijk FDH, Broek IVF van den. et al. Sexually transmitted infections, including HIV, in the Netherlands in 2013. Bilthoven: RIVM; 2014. reportnumber 150002005/2014.

    Google Scholar 

  9. Kok IM de, Habbema JD, Rosmalen J van, Ballegooijen M van. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer. 2011;47(3):428–35.

    Article  PubMed  Google Scholar 

  10. Integraal Kankercentrum Nederland (IKNL). http://cijfersoverkanker.nl/. Geraadpleegd op: 1 november 2016.

  11. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62.

    Article  PubMed  PubMed Central  Google Scholar 

  12. GlaxoSmithKline Vaccine HPVSG, Romanowski B, Borba PC de, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet. 2009;374(9706):1975–85.

    Article  Google Scholar 

  13. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4‑year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89–99.

    Article  CAS  PubMed  Google Scholar 

  14. FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.

    Article  Google Scholar 

  15. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–23.

    Article  CAS  PubMed  Google Scholar 

  16. Moreira ED Jr., Block SL, Ferris D, et al. Safety profile of the 9‑Valent HPV vaccine: a combined analysis of 7 phase III clinical trials. Pediatrics. 2016;138(2):pii: e20154387.

    Article  Google Scholar 

  17. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781–9.

    Article  CAS  PubMed  Google Scholar 

  18. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–F138.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325–39.

    Article  CAS  PubMed  Google Scholar 

  20. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301–14.

    Article  CAS  PubMed  Google Scholar 

  21. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Rijksvaccinatieprogramma 2016. http://www.rivm.nl/Onderwerpen/R/Rijksvaccinatieprogramma/Professionals. Geraadpleegd op: 19 oktober 2016.

    Google Scholar 

  22. Rijksinstituut voor Volksgezondheid en Milieu (RIVM). Wijziging HPV-vaccinatieschema: 1 prik minder 2014. http://www.rivm.nl/Documenten_en_publicaties/Algemeen_Actueel/Uitgaven/Infectieziekten_Bulletin/Jaargang_25_2014/Februari_2014/Inhoud_Februari_2014/Wijziging_HPV_vaccinatieschema_1_prik_minder. Geraadpleegd op: 19 oktober 2016.

    Google Scholar 

  23. Lier EA van, Oomen PJ, Giesbers H. et al. Rijksinstituut voor Volksgezondheid en Milieu (RIVM), Vaccinatiegraad Rijksvaccinatieprogramma Nederland, Verslagjaar 2015, RIVM rapport 2015-0067. Bilthoven: RIVM; 2015.

    Google Scholar 

  24. Karsa L von, Arbyn A, Vuyst H de. et al. Executive summary. In: Anttila A, Arbyn A, Vuyst H de et al. (redactie). European guidelines for quality assurance in cervical cancer screening, 2e druk. Luxembourg: Office for Official Publications of the European Union; 2015. pp. XIII–XXIV.

    Google Scholar 

  25. Elfstrom KM, Dillner J, Arnheim-Dahlstrom L. Organization and quality of HPV vaccination programs in Europe. Vaccine. 2015;33(14):1673–81.

    Article  PubMed  Google Scholar 

  26. Australian Government, Department of Health. November 2011 PBAC outcomes – positive recommendations 2011. http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/2011-11/positive-recommendations. Geraadpleegd op: 1 november 2016.

    Google Scholar 

  27. Public Health Agency of Canada, National Advisory Committee on Immunization (NACI). Update on human papillomavirus (HPV) vaccines 2012. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/assets/pdf/12vol-38-acs-dcc-1-eng.pdf. Geraadpleegd op: 1 november 2016.

    Google Scholar 

  28. Centers for Disease Control and Prevention, Markowitz LE, et al. Sexually Transmitted Diseases Treatment Guidelines 2010. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(RR05):1–30.

    Google Scholar 

  29. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries – an update. Stockholm: ECDC; 2012.

    Google Scholar 

  30. Skeate JG, Woodham AW, Einstein MH, Silva DM da, Kast WM. Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases. Hum Vaccin Immunother. 2016;12(6):1418–29.

    Article  PubMed  Google Scholar 

  31. Solares AM, Baladron I, Ramos T, et al. Safety and Immunogenicity of a human papillomavirus peptide vaccine (CIGB-228) in women with high-grade cervical intraepithelial neoplasia: first-in-human, proof-of-concept trial. ISRN Obstet Gynecol. 2011;2011:292951.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kim TJ, Jin HT, Hur SY, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun. 2014;5:5317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gezondheidsraad. Screening op baarmoederhalskanker. Den Haag: Gezondheidsraad; 2011.

    Google Scholar 

  34. Rozemeijer K, Van Rosmalen J, Naber SK, Penning C, De Kok IMCM, Van Ballegooijen M. Kosteneffectiviteitsanalyse primaire hrHPV-screening zonder versus met hrHPV-zelftest. Rotterdam: Erasmus MC, Universitair Medisch Centrum Rotterdam; 2013.

    Google Scholar 

  35. Wheeler CM, Skinner SR, Rosario-Raymundo MR del, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7‑year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154–68.

    Article  CAS  PubMed  Google Scholar 

  36. Munoz N, Manalastas R Jr., Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57.

    Article  CAS  PubMed  Google Scholar 

  37. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Afdeling Maatschappelijke Gezondheidszorg, Erasmus MC, Rotterdam, Nederland

    Inge M. C. M. de Kok & Suzette M. Matthijsse

Authors
  1. Inge M. C. M. de Kok
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Suzette M. Matthijsse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Inge M. C. M. de Kok.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Kok, I.M.C.M., Matthijsse, S.M. HPV-vaccinatie. Bijblijven 33, 29–40 (2017). https://doi.org/10.1007/s12414-016-0200-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12414-016-0200-z

Search

Navigation